



## Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

March 10, 2022

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- [Amicus Therapeutics](#) (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the [2022 MDA Clinical & Scientific Conference](#), being held March 13-16, 2022 in Nashville, TN and virtually.

### Oral Platform Presentation:

**Wednesday, March 16, 12:10 p.m. CST**

- **Abstract Title:** *Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02)*  
**Presenter:** Barry Byrne, MD, PhD, University of Florida Health, Gainesville, FL, U.S.A.  
**Location:** Tennessee Ballroom

### Poster Presentations:

- **Abstract Title:** *Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset pompe disease: A phase III, randomized study (PROPEL)*  
**Presenter:** Tahseen Mozaffar, MD, University of California, Irvine, CA, U.S.A.  
**Location:** Ryman Exhibit Hall B1-2, Poster #65
- **Abstract Title:** *Living with Pompe disease in the UK: Characterizing the patient journey; burden on physical and emotional quality of life; and impact of COVID-19*  
**Presenter:** Derralynn Hughes, BMBCh, University College London, London, U.K.  
**Location:** Virtual

The posters and presentation will be made available on the Amicus [website](#) following their respective presentations at the conference.

For more information on the 2022 MDA Clinical & Scientific Conference, please visit [www.mdaconference.org](http://www.mdaconference.org).

### About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company's website at [www.amicusrx.com](http://www.amicusrx.com), and follow us on [Twitter](#) and [LinkedIn](#).

### **CONTACTS:**

#### **Investors:**

Amicus Therapeutics  
Andrew Faughnan  
Executive Director, Investor Relations  
[afaughnan@amicusrx.com](mailto:afaughnan@amicusrx.com)  
(609) 662-3809

#### **Media:**

Amicus Therapeutics  
Diana Moore  
Head of Global Corporate Communications  
[dmoore@amicusrx.com](mailto:dmoore@amicusrx.com)  
(609) 662-5079

FOLD-G